Gadodiamide

Source: Wikipedia, the free encyclopedia.

Gadodiamide
Clinical data
Trade namesOmniscan
Other names2-[bis[2-(carboxylatomethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetate; gadolinium(+3) cation
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein bindingnegligible
Metabolismnot metabolized
Elimination half-life77.8 minutes
ExcretionKidney
Identifiers
  • gadolinium(III) 5,8-bis(carboxylatomethyl)-2-[2-(methylamino)-2-oxoethyl]-10-oxo-2,5,8,11-tetraazadodecane-1-carboxylate hydrate
JSmol)
  • [Gd+3].[O-]C(=O)CN(CC(=O)NC)CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O
  • InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3 checkY
  • Key:HZHFFEYYPYZMNU-UHFFFAOYSA-K checkY
 ☒NcheckY (what is this?)  (verify)

Gadodiamide, sold under the brand name Omniscan, is a

gadolinium-based MRI contrast agent (GBCA), used in magnetic resonance imaging
(MRI) procedures to assist in the visualization of blood vessels.

Medical uses

Further information: MRI contrast agent
A bottle of Omniscan contrast agent.

Gadodiamide is a

blood brain barrier.[5]

Adverse effects

Gadodiamide is one of the main GBCA associated with

kidney problems.[6] No cases have been seen in people with normal kidney function.[7]

A 2015 study found gadolinium deposited in the brain tissue of people who had received gadodiamide.[8] Other studies using post-mortem mass spectrometry found most of the deposit remained at least 2 years after an injection and deposit also in individuals with no kidney issues.

In vitro studies found it to be neurotoxic.[9]

An Italian task force recommended that breastfeeding mothers precautionally avoid any contrast agent, such as gadodiamide, that has been associated with nephrogenic systemic fibrosis.[10]

Society and culture

Gadodiamide was suspended along with gadopentetic acid (Magnevist) by the European Medicines Agency in 2017.[11]

References

  1. FDA
    . Retrieved 22 October 2023.
  2. ^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
  3. ^ "Omniscan- gadodiamide injection". DailyMed. Retrieved 29 August 2021.
  4. ^ "Active substance: gadodiamide" (PDF). List of nationally authorised medicinal products. European Medicine Agency. 14 January 2021.
  5. PMID 32246802
    .
  6. PMID 29494094
    .
  7. PMID 18587720
    .
  8. ^ Anderson P (26 March 2015). "Gadolinium Found in Brain Tissue". Medscape. Retrieved 14 April 2015.
  9. S2CID 164486744
    .
  10. S2CID 24502257
    .
  11. ^ "Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents". GOV.UK. 14 December 2017. Retrieved 29 August 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Gadodiamide&oldid=1216057623"